$BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells$

BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells

BACKGROUND: Although pazopanib treatment has become the standard chemotherapy in salvage setting for metastatic sarcoma patients, most patients progress after pazopanib treatment in 4 to 6 months. After failure to pazopanib, patients have limited options for treatment. Therefore, subsequent therapy...

Full description

Bibliographic Details
Main Authors:	Hee Kyung Kim, Sun Young Kim, Su Jin Lee, Mihyeon Kang, Seung Tae Kim, Jiryeon Jang, Oliver Rath, Julia Schueler, Dong Woo Lee, Woong Yang Park, Sung Joo Kim, Se Hoon Park, Jeeyun Lee
Format:	Article
Language:	English
Published:	Elsevier 2016-06-01
Series:	Translational Oncology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523316300092

Similar Items

NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/ mTOR phosphorylation
by: Sun ZH, et al.
Published: (2015-01-01)

RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth.
by: Beat Nyfeler, et al.
Published: (2012-01-01)

Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
by: Shu-Fu Lin, et al.
Published: (2012-01-01)

The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.
by: Jatin Roper, et al.
Published: (2011-01-01)

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
by: Keiko Shoji, et al.
Published: (2012-01-01)

BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy
by: Weiya Cao, et al.
Published: (2021-01-01)

Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy
by: Li L, et al.
Published: (2018-09-01)

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
by: Demartines Nicolas, et al.
Published: (2011-07-01)

The combined effects of the dual PI3K/mTOR inhibitor BEZ235 with cisplatin or etoposide in small cell lung cancer
by: Tsai, Hong-Yi, et al.
Published: (2016)

Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment
by: Moorthy, Ganesh
Published: (2015)

Dual PI3K/mTOR Inhibition with BEZ235 Augments the Therapeutic Efficacy of Doxorubicin in Cancer without Influencing Cardiac Function
by: Durrant, David E.
Published: (2015)

Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
by: Yu-Hsuan Chen, et al.
Published: (2019-08-01)

Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions
by: Sebastian Kuger, et al.
Published: (2014-01-01)

Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions
by: Sebastian Kuger, et al.
Published: (2014-03-01)

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
by: Fabian Lang, et al.
Published: (2020-09-01)

The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway
by: Xiaolong Tang, et al.
Published: (2020-03-01)

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils.
by: Katharina Blatt, et al.
Published: (2012-01-01)

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses
by: Bipasha Mukherjee, et al.
Published: (2012-01-01)

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
by: Xin P, et al.
Published: (2017-04-01)

Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis
by: Zou H, et al.
Published: (2016-05-01)

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
by: Sabina Luszczak, et al.
Published: (2020-09-01)

PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
by: Sang Kyum Kim, et al.
Published: (2021-03-01)

The anti-cancer effect of the dual PI3K/mTOR inhibitor, NVP-BEZ235, on non-small cell lung cancer harboring wild-type EGFR
by: Hung-ChangWu, et al.
Published: (2013)

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
by: Hyera Kim, et al.
Published: (2020-04-01)

The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens
by: Yi-Ying Wu, et al.
Published: (2019-07-01)

Pazopanib for the treatment of soft-tissue sarcoma
by: Heudel P, et al.
Published: (2012-10-01)

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
by: Wagle, N., et al.
Published: (2015)

The PI3K/mTOR dual inhibitor NVP‐BEZ235 stimulates mutant p53 degradation to exert anti‐tumor effects on triple‐negative breast cancer cells
by: Jiajing Cai, et al.
Published: (2020-04-01)

Synergy of NVP-BEZ235 and enzastaurin in mantle cell lymphoma
by: Monica Civallero, et al.
Published: (2014-03-01)

Activity of BKM120 and BEZ235 against Lymphoma Cells
by: Monica Civallero, et al.
Published: (2015-01-01)

The mechanisms of radioresistance and BEZ235 as a radiosensitizer in cancer treatment
by: Yu-Hsuan Chen, et al.
Published: (2015)

Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
by: Li Tian, et al.
Published: (2018-01-01)

Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma
by: Jinhyun Cho, et al.
Published: (2016-10-01)

Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis
by: Hu Y, et al.
Published: (2021-03-01)

Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience
by: Ninna Aggerholm-Pedersen, et al.
Published: (2020-02-01)

Pazopanib in the management of advanced soft tissue sarcomas
by: Cranmer LD, et al.
Published: (2016-06-01)

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
by: Lampidis Theodore, et al.
Published: (2005-07-01)

Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma
by: Ofer Merimsky, et al.
Published: (2008-01-01)

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
by: Filip Janku, et al.
Published: (2014-01-01)

Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
by: Pooja Shah, et al.
Published: (2020-09-01)